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Objective: Age-standardized burden of cardiovascular diseases is substantially higher in low
and middle-income countries than in high-income countries. However, Indian patients are
not getting access to the new cardiovascular drugs at the same time as patients in the
developed nations. The objective of this study was to assess the drug lag for new cardio-
vascular drugs in India compared with that in the United States (US) or European Union
(EU).
Methods: The information regarding approval of new cardiovascular drugs in the United
States, European Union and India between 1999 and 2011 were obtained primarily from the
online databases of regulatory agencies. The approval lag was obtained for all new
cardiovascular drugs approved in each region, and the median approval lag was calculated
for each region.
Results: Of the 75 new cardiovascular drugs, 61 (81.33%) were approved in the United States,
65 (86.66%) in the European Union and 56 (74.66%) in India. The US was the first to approve
35 (56.45%) out of the 75 new cardiovascular drugs, the EU was the first to approve
24 (38.71%) and India was the first to approve 3 (4.84%). The median approval lag for India
(44.14 months) was substantially higher as compared to the United States (0 month) and
European Union (2.99 months).
Conclusion: This study confirms that there is a substantial drug lag in approval of new
cardiovascular drugs in India compared with the United States and European Union. The
impact of drug lag on health outcomes remains to be established.
Copyright ª 2012, Cardiological Society of India. All rights reserved.1. Introduction may be driven by the development and better utilization ofThe last four decades has seen major advances in the
prevention, diagnosis, and treatment of cardiovascular
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getting access to the new medicines at the same time as
patients in the developed nations. The timeliness with which
drug regulatory authorities approve new drugs for marketing
affects health care professionals and patients. A long approval
process delays access to new medicines that may improve
patients’ health status.
Each country has specific regulatory controls that govern
approval of new drugs; however, these controls often differ
from country to country. Therefore, the time required for
approval of a new drugmay vary depending on each country’s
regulatory process. There is a change in the regulatory envi-
ronment after a system of product patents in India since
2005.4 The main regulatory body for the Indian pharmaceu-
tical industry is the Central Drugs Standard Control Organi-
zation (CDSCO). The Drug Controller General of India (DCGI) is
the controlling body for the CDSCO. The office of the DCGI is
responsible for the approval of new drugs and clinical trials.
Drug lag has been a debated issue in the United States (US)
and Europe during the 1970s and 1980s.5,6 However, the drug
lag issue has not been addressed seriously in India. Because of
increasing use of internet in India, many healthcare profes-
sionals and general public are now aware of the treatment
options available in the developed regions. The drug lag
prevents Indian patients from accessing new drugs at the
same time as patients in the developed nations. Further, it
may even delay the progress of clinical research in India.
Therefore, identifying the actual status of the cardiovascular
drug lag in India would provide important information that
could be used in efforts to resolve this issue. The purpose of
this study was to assess the drug lag for new cardiovascular
drugs approved in India, in comparison with the approval of
new cardiovascular drugs in the US and European Union (EU).2. Methods
2.1. Data sources of new cardiovascular drug approvals
New cardiovascular drugs approved in the US, EU, or India
between 1999 and 2011 were identified by their International
Nonproprietary Names (INN), and information was gathered
primarily from the following sources:
1. The US: The Center for Drug Evaluation and Research
(CDER) New Molecular Entity (NME) and New Biological
Approvals, US Food and Drug Administration (FDA),7
2. The EU: The European Public Assessment Report (EPAR),
Committee for Medicinal Products for Human Use (CHMP),
European Medicines Agency (EMA),8
3. India: The Central Drugs Standard Control Organization
(CDSCO) List of drug approved for marketing in India.9
Information about name of approved drug, indication and
date of issue of marketing approval was retrieved from the
above sources. New cardiovascular drugs were defined as
drugs having an active ingredient that has never before been
marketed in the US, EU or India in any form. The following
drugs were excluded: (a) vaccines and (b) combination drugs
that do not include any new drugs.2.2. Analyses of drug lag
In this study, we assessed and described the drug lag in the
three regions in terms of ‘absolute drug lag’ and ‘relative drug
lag’. In assessing absolute drug lag, we used as variables the
number and the percentage of approved new cardiovascular
drugs in each region out of a total of new cardiovascular drugs
approved either in the three regions in the study period. In
assessing relative drug lag, two variables were used; one
variable was the number and percentage of first approvals in
the regions out of a total of new cardiovascular drugs
approved either in the three regions in the study period, and
the other variable was the approval lag against the first
approval granted to each cardiovascular drug in the three
regions. For example, if the US was the first to approve
a cardiovascular drug in February 2010 and if India approved
the same cardiovascular drug in December 2010, the
approval lag for the US is 0, and the approval lag for India is 10
months.
The approval lag was obtained for all new cardiovascular
drugs approved in each region, and the median approval lag
was calculated for each region. In the European Union, the
European Medicines Agency was established in 1993 to unify
regulatory practice within the EU. The centralized procedure
for marketing authorization of drugs throughout the EU went
into operation in 1995. So, alternatively, we searched the
Medicines and Healthcare products Regulatory Agency
(MHRA) of United Kingdom (UK) approval date for the
cardiovascular drugs for which EU approval date was not
available. The UK approval dates were obtained from the
electronic medicines compendium.10 The new cardiovascular
drugs for which approval dates were unknown were excluded
from the calculation of median approval lag.
Additionally, for the FDA approved drugs, the information
about review type (standard/priority/orphan drug status) was
obtained from the FDA online database.73. Results
3.1. New cardiovascular drugs approved in the US, EU
and India
We identified 75 new cardiovascular drugs approved either in
the US, the EU, or India between 1999 and 2011. Of these 75
new cardiovascular drugs, 35 were mutually approved in the
three regions. The US and the EU approved 19 cardiovascular
drugs that were not approved in India. The EU and India
approved 14 cardiovascular drugs that were not approved in
the US. The US and India approved 10 cardiovascular drugs
that were not approved in the EU. Total 54 new cardiovascular
drugs were approved in India during the period of 1999e2011,
with an average of 4.15 new cardiovascular drugs approved
per year. For the same period a total of 34 new cardiovascular
drugs were approved in the US, with an average of 2.61
cardiovascular drugs approved per year and in the EU a total of
23 new cardiovascular drugs were approved, with an average
of 1.76 cardiovascular drugs approved per year. The year wise
distribution of new cardiovascular drugs approved in the US,
EU and India is shown in Fig. 1.
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Fig. 1 e New cardiovascular drugs approved in the US, EU
and India, 1999e2011.
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Fig. 2 e Distribution of drug lag for new cardiovascular
drugs approved in the US, EU and India. *The distribution
is shown in 24-month interval.
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The absolute drug lags for the US, the EU and India are shown
in Table 1. Of the 75 new cardiovascular drugs, 61 (81.33%)
were approved in the US, 65 (86.66%) in the EU and 56 (74.66%)
in India.
The relative drug lags for the US, the EU and India are
summarized in Table 1. The US was the first to approve 35
(56.45%) out of the 75 new cardiovascular drugs, the EU was
the first to approve 24 (38.71%) and India was the first to
approve 3 (4.84%). The median approval lag for India (44.14
months) was substantially higher as compared to the United
States (0 month) and European Union (2.99 months). The
distributions of approval lags for each region are shown in
Fig. 2. Although the approval lag was less than 24 months for
most of the cardiovascular drugs for the US and the EU, India
had a different distribution profile. The 13 new cardiovascular
drugs were approved in India within first 24 months of drug
lag interval and showed a wide distribution up to nearly 400
months (Fig. 2).
The relative drug lag was assessed for the 35 ‘mutually
approved new cardiovascular drugs’. The US was the first to
approve 24 (68.57%) out of the 35 mutually approved new
cardiovascular drugs, the EU was the first to approve 11
(31.43%) and India was not the first to approve any mutually
approved new cardiovascular drugs. Again the median
approval lag for India (45.46 months) was substantially higher
as compared to the United States (0.0 month) and European
Union (8 months) for the mutually approved new cardiovas-
cular drugs.
The approval dates and characteristics of new cardiovas-
cular drugs approved either in the US, EU or India is shown inTable 1 e Absolute and relative drug lag of new
cardiovascular drugs for the US, EU and India (n[ 75).
US EU India
Number of approvals 61 (81.33%) 65 (86.66%) 56 (74.66%)
Number of first approvals 35 (56.45%) 24 (38.71%) 3 (4.84%)
Median approval lag
(months)
0 (n ¼ 52) 2.99 (n ¼ 52) 44.14 (n ¼ 44)Table 2. Of the 61 new cardiovascular drugs that were
approved by the FDA, 14 were priority review drugs; 46 were
standard review drugs; 6 received orphan drug status and the
US review type status was not available for one drug.4. Discussion
The percentage of approval of new cardiovascular drugs was
more than 80% for the US and EU, 56 (74.66%) of the 75 new
cardiovascular drugs were approved in India. Thus, India is
slightly behind in comparison to the US and EU regions in
terms of absolute drug lag. The US was the first to approve the
majority of the new cardiovascular drugs, and the EU was
slightly delayed (Median approval lag: 2.99 months). But, the
substantial delay was observed for India in approval of new
cardiovascular drugs. Themedian approval lag for India (44.14
months) was almost four years longer than that for the US and
EU. While our study showed that the US was first to approve
majority of the new cardiovascular drugs, the relative drug lag
for EU was not so high. Therefore, it can be assumed that the
drug lag in the EUwas simply a slight delay in approval, which
may be attributed to a delay in the start of development and
may be a slightly longer review period.
A possible reason for the delays in approval of new
cardiovascular drugs in India may be that pharmaceutical
companies believe that simultaneously conducting registra-
tion trials in India and in the US or EU is a risk. As per World
Trade Organization (WTO), from the year 2005, India granted
product patent recognition to all new chemical entities (NCEs).
Though, many foreign multinational corporations (MNCs) are
not taking risk to launch their patented new drugs in India
simultaneouslywith the developedmarkets. To resolve delays
in the initiation of drug development in India, pharmaceutical
companies should make an effort to enroll Indian patients in
international registration trials. For majority of new drugs,
drug development is being performed in the US and the EU
concurrently, and the integrated data packagemay be used for
new drug applications (NDAs) in the US and the EU. Thus, it
was not surprising that there was a little time gap in new drug
approvals between the US and the EU.
Table 2 e Approval dates and characteristics of new cardiovascular drugs approved either in the US, EU or India from 1999
through 2011 (n[ 75).
Generic name (INN) Indication US approval
date
EU approval
date
India approval
date
US review
classification
Azilsartan medoxomil Hypertension 25-Feb-2011 7-Dec-2011 NA S
Rivaroxaban Venous thromboembolism 1-Jul-2011 30-Sep-2008 30-Jan-2010 S
Ticagrelor Acute coronary syndrome 20-Jul-2011 3-Dec-2010 NA S
Icatibant acetate Hereditary angioedema 25-Aug-2011 11-Jul-2008 NA P,O
Polidocanol Varicose veins 30-Mar-2010 NA NA S
Dabigatran etexilate Venous thromboembolism 19-Oct-2010 18-Mar-2008 12-Dec-2011 P
Tolvaptan Inappropriate ADH Syndrome 19-May-2009 3-Aug-2009 NA S
Dronedarone Atrial fibrillation 1-Jul-2009 26-Nov-2009 8-Apr-2010 P
Prasugrel Acute coronary syndrome 10-Jul-2009 23-Feb-2009 13-Apr-2010 P
Pitavastatin Dyslipidemias 3-Aug-2009 NA 14-Jan-2005 S
Ecallantide Hereditary angioedema 1-Dec-2009 NA NA P,O
Regadenoson Myocardial Perfusion Imaging 10-Apr-2008 6-Sep-2010 NA S
Clevidipine Hypertension 1-Aug-2008 NA NA S
Aliskiren Hypertension 5-Mar-2007 22-Aug-2007 8-Jun-2007 S
Ambrisentan Pulmonary arterial hypertension 15-Jun-2007 21-Apr-2008 24-May-2010 P,O
Nebivolola Hypertension 17-Dec-2007 4-Jan-1999 12-Jul-2002 S
Ranolazine Angina pectoris 27-Jan-2006 9-Jul-2008 14-Jun-2007 S
Conivaptan Inappropriate ADH Syndrome 29-Dec-2005 NA NA S
Omega-3-acid ethyl estersa Hypertriglyceridaemia 10-Nov-2004 22-Jul-2001 NA S
Iloprost Pulmonary arterial hypertension 29-Dec-2004 16-Sep-2003 NA P,O
Rosuvastatina Dyslipidemias 12-Aug-2003 21-Mar-2003 12-Sep-2003 S
Olmesartan medoxomila Hypertension 25-Apr-2002 22-May-2003 21-Jul-2005 S
Treprostinil Pulmonary arterial hypertension 21-May-2002 NA NA P,O
Eplerenonea Hypertension 27-Sep-2002 21-Sep-2004 10-Jun-2005 S
Ezetimibe Dyslipidemias 25-Oct-2002 1-Oct-2002 18-Dec-2003 S
Nesiritide Acutely decompensated heart failure 10-Aug-2001 NA NA S
Bosentan Pulmonary arterial hypertension 20-Nov-2001 15-May-2002 23-Jun-2009 S,O
Fondaparinux Venous thromboembolism 7-Dec-2001 21-Mar-2002 22-Oct-2003 P
Colesevelam Hypercholesterolemia 26-May-2000 10-Mar-2004 NA S
Argatroban Anticoagulant for prophylaxis or
treatment of thrombosis in patients with
heparin-induced thrombocytopenia
30-Jun-2000 A NA S
Tinzaparina Venous thromboembolism 14-Jul-2000 20-Nov-1997 A S
Bivalirudin In patients with unstable angina
undergoing PTCA
15-Dec-2000 20-Sep-2004 25-Aug-2005 S
Cilostazola Intermittent claudication 15-Jan-1999 21-Mar-2000 23-Jan-2003 S
Dofetilide Atrial fibrillation 1-Oct-1999 29-Nov-1999 NA S
Vernakalant Atrial fibrillation NA 1-Sep-2010 NA
Ivabradine Angina pectoris NA 25-Oct-2005 3-Jul-2008
Apixaban Venous thromboembolism NA 18-May-2011 NA
Eptifibatide Acute coronary syndrome 18-May-1998 1-Jul-1999 25-Aug-1999 P
Tenecteplase Myocardial infarction 2-Jun-2000 23-Feb-2001 A e
Laropiprant/
Nicotinic acid
Dyslipidemias NA 3-Jul-2008 26-Mar-2010
Conestat alfa Hereditary angioedema NA 28-Oct-2010 NA
Sarpogrelate Chronic arterial occlusion NA NA 16-Jan-2010
Levosimendan Acutely decompensated heart failure NA NA 30-Apr-2010
Nadolola Angina pectoris 10-Dec-1979 24-Nov-1995 20-Aug-2010 S
Perindoprila Hypertension 30-Dec-1993 28-Feb-2007 16-May-2009 S
Chlorthalidone Hypertension 7-Apr-1960 A 3-Oct-2009 P
Acipimoxa Dyslipidemias NA 2-May-2003 26-Nov-2009
Nicardipinea Hypertension 21-Dec-1988 15-May-1998 7-Apr-2008 S
Eprosartana Hypertension 22-Dec-1997 23-Aug-1999 11-Oct-2008 S
Moxonidinea Hypertension NA 15-Sep-1997 27-Feb-2007
Cholestyraminea Hypercholesterolemia 3-Aug-1973 25-Jul-1988 30-Mar-2006 S
Bemiparin Venous thromboembolism NA A 8-Jun-2006
Imidapril Hypertension NA A 23-Feb-2004
Metolazone Hypertension 27-Nov-1973 A 23-Apr-2003 S
Torsemide Hypertension 23-Aug-1993 NA 9-Jun-2003 S
Bendroflumethiazide Hypertension 7-Dec-1959 A 24-Jul-2003 S
Tirofibana Acute coronary syndrome 14-May-1998 15-Jul-1999 12-Aug-2003 P
Trandolaprila Hypertension 26-Apr-1996 25-Nov-1992 3-Oct-2003 S
(continued on next page)
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Table 2 e (continued )
Generic name (INN) Indication US approval
date
EU approval
date
India approval
date
US review
classification
Fluvastatina Dyslipidemias 31-Dec-1993 23-Aug-1993 25-Nov-2003 S
Fosinopril Hypertension 16-May-1991 A 10-Jan-2002 S
Lercanidipine Hypertension NA 22-Mar-1996 7-May-2002
Quinaprila Hypertension 19-Nov-1991 3-Aug-1990 19-Sep-2002 S
Telmisartan Hypertension 10-Nov-1998 16-Dec-1998 25-Nov-2002 S
Triflusal Prophylaxis of thromboembolic disorders NA A 17-Jan-2001
Clopidogrel ACS, MI, PVD, Stroke 17-Nov-1997 15-Jul-1998 22-Feb-2001 P
Valsartana Hypertension 23-Dec-1996 31-Oct-1997 10-Dec-2001 S
Trapidil Adjunct in angioplasty NA A 11-May-2000
Cerivastatin Dyslipidemias 26-Jun-1997 A 11-May-2000 S
Irbesartan Hypertension 30-Sep-1997 27-Aug-1997 26-Jun-2000 S
Candesartana Hypertension 4-Jun-1998 15-Dec-1998 31-Aug-2000 S
Pravastatina Dyslipidemias 31-Oct-1991 31-Oct-1997 20-Dec-2000 S
Doxazosin Hypertension 2-Nov-1990 A 11-Mar-1999 S
Milrinonea Acutely decompensated heart failure 31-Dec-1987 11-Oct-1989 17-May-1999 S
Atorvastatina Dyslipidemias 17-Dec-1996 8-Sep-1997 17-Sep-1999 P
Fenofibratea Dyslipidemias 31-Dec-1993 1-Nov-1993 22-Dec-1999 S
INN: international nonproprietary name, NA: not available, A: available, but approval date is not known, ADH: antidiuretic hormone, PTCA:
percutaneous transluminal coronary angioplasty, ACS: acute coronary syndrome, MI: myocardial infarction, PVD: peripheral vascular diseases,
P: Priority review drug, S: Standard review drug, O: Orphan drug.
a UK approval date.
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FDA and EMA. European Medicines Agency did not authorize
nesiritide, awaiting longer-term data on renal side effects and
mortality and a large randomized study. However, nesiritide
was approved by the FDA in 2001 with similar data.7 There
was criticism about pro industry culture in the FDA that
favored drug approval than its European counterparts. One of
the reasons that might contribute to this culture is the
prescription drug user fee act of FDA, which has allowed
industry sources to direct funding to the FDA to help speed
new drug approval.11 The average approval time dropped from
27months in1993,whenuser feeswere instituted, to19months
in 2001.12 The FDA didn’t approve a new combination of niacin
and laropiprant, an agent to prevent flushing. However, the
same combination is approved by the EMA and DCGI.
In August 2001, cerivastatin was removed from the world
market because of a higher risk of rhabdomyolysis associated
with its use in comparison with other statins.13 Safety-based
withdrawals of drugs or their labels, however, show a benefi-
cial aspect of the drug lag. A typical example is Rofecoxib,
which was withdrawn from the market because of its asso-
ciation with cardiovascular problems in September 2004.14 In
the area of psychiatric drugs, the black box warnings of anti-
depressants for children15 and of antipsychotics for the
elderly with dementia16 are cases where the drug lag has
helped patients to avoid exposure to potentially harmful
drugs. The general public as well as most healthcare profes-
sionals believe that the drug lag is always bad for patients, but
its impact on health outcomes is unknown.
A study of the therapeutic significance of the drug lag in the
USA in the 1970s17 showed that only 14% of 198 drugs
reviewed offered a potential therapeutic advance, whereas
75% appeared to offer little or no advance. There is a large gap
between India and the west with regard to timing of approval
of new cardiovascular drugs. This may be because the US orEurope based companies were not interested to introduce the
new cardiovascular drugs through their subsidiaries in India
due to relaxed patent law in India before 2005. Themajority of
largemultinational pharmaceutical companies have presence
in India and they may try to introduce their new products in
India, simultaneously with other markets. Now, because of
product patent in India, the Indian pharmaceutical companies
can’t introduce patented drugs developed by the foreign
MNCs. With the introduction of product patents, Indian
companies will have to shift the area of focus from process
development to developing new drug products. However,
there is a need to improve the regulatory processes in India to
enhance the clinical trials and new drug approvals. The Indian
regulatory authority has to initiate some measures to reduce
this delay in approval. The Japanese government has initiated
various direct and indirect measures to reduce drug lag in
Japan.18 There is an urgent need to increase the human
resources and improvement in the regulatory processes in
India.
Due to the limitations of this study, it is not possible to
make an analysis of the possible reasons behind the delays in
approval of new cardiovascular drugs in India. However, delay
in the start of development, delay in the progress of devel-
opment and delay in review by the regulatory authority could
be possible reasons behind this lag in approval of cardiovas-
cular drugs in India.
In conclusion, this study confirms that there is still a large
gap between India and the West with regard to access to new
cardiovascular drugs. The drug lag in India may be attributed
to a delay in the start of development, a delay in the progress
of development, late submission of NDA and a delay in review
by the regulatory authority. The impact of the drug lag on
health outcomes remains to be established. To reduce drug
lag, combined efforts are required by the Indian regulatory
agency and pharmaceutical companies.
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